{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:10Z","timestamp":1788798430095,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.juro.2010.05.085","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T09:07:29Z","timestamp":1282208849000},"page":"1507-1513","source":"Crossref","is-referenced-by-count":35,"title":["Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer"],"prefix":"10.1097","volume":"184","author":[{"given":"Miguel","family":"Alvarez-M\u00fagica","sequence":"first","affiliation":[{"name":"Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain"},{"name":"Urology Department, Hospital Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Cebrian","sequence":"additional","affiliation":[{"name":"Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Fern\u00e1ndez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentino","family":"Fresno","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwan","family":"Escaf","sequence":"additional","affiliation":[{"name":"Urology Department, Hospital Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"S\u00e1nchez-Carbayo","sequence":"additional","affiliation":[{"name":"Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.05.085_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.juro.2010.05.085_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.seminoncol.2006.12.013","article-title":"Molecular alterations associated with bladder cancer progression","volume":"34","author":"Sanchez-Carbayo","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.juro.2010.05.085_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the superficial bladder tumor","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000052376","article-title":"Preventing progression and improving survival with BCG maintenance","volume":"1","author":"Lamm","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","article-title":"Intravesical bacillus Calmette Guerin treatment improves patient survival in T1G3 bladder tumors","volume":"41","author":"Patard","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist?","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib8","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-5347(06)00593-3","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy","volume":"176","author":"Palou","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.05.085_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.2390","article-title":"Discovery of myopodin methylation in bladder cancer","volume":"216","author":"Cebrian","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.juro.2010.05.085_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1083\/jcb.200012039","article-title":"Differentiation- and stress-dependent nuclear cytoplasmic redistribution of myopodin, a novel actin-bundling protein","volume":"155","author":"Weins","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.juro.2010.05.085_bib14","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1074\/jbc.M209946200","article-title":"The Nucleo-cytoplasmic actin-binding protein CapG lacks a nuclear export sequence present in structurally related proteins","volume":"278","author":"Van Impe","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.juro.2010.05.085_bib15","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0002-9440(10)63006-4","article-title":"Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers","volume":"159","author":"Lin","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.juro.2010.05.085_bib16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0002-9440(10)63738-8","article-title":"Expression of myopodin induces suppression of tumor growth and metastasis","volume":"164","author":"Jing","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.juro.2010.05.085_bib17","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1158\/0008-5472.CAN-06-0227","article-title":"Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin","volume":"66","author":"Yu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2010.05.085_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.urology.2006.03.027","article-title":"Inactivation of myopodin expression associated with prostate cancer relapse","volume":"68","author":"Yu","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.05.085_bib19","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1038\/sj.onc.1206616","article-title":"Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome","volume":"22","author":"S\u00e1nchez-Carbayo","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.juro.2010.05.085_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1083\/jcb.200411169","article-title":"Promotion of import alpha-mediated nuclear import by the phophorylation-dependent binding of cargo protein to 14-3-3","volume":"169","author":"Faul","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.juro.2010.05.085_bib21","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1016\/j.febslet.2005.10.054","article-title":"A monopartite nuclear localization sequence regulates nuclear targeting of the actin binding protein myopodin","volume":"579","author":"De Ganck","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.juro.2010.05.085_bib22","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1128\/MCB.00950-07","article-title":"Protein kinase A, Ca2+\/calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes","volume":"27","author":"Faul","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.juro.2010.05.085_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11010-007-9588-1","article-title":"Interaction between importin 13 and myopodin suggests a nuclear import pathway for myopodin","volume":"307","author":"Liang","year":"2008","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.juro.2010.05.085_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.juro.2010.05.085_bib25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2005.03.2375","article-title":"Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays","volume":"24","author":"Sanchez-Carbayo","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.05.085_bib26","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.bjc.6604143","article-title":"Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays","volume":"98","author":"Aleman","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2010.05.085_bib27","series-title":"Basic and Clinical Biostatistics","author":"Dawson-Saunders","year":"1994"},{"key":"10.1016\/j.juro.2010.05.085_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","article-title":"Cumulative incidence in competing risks data and competing risks regression analysis","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.05.085_bib29","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/sim.3402","article-title":"Analyses of cumulative incidence functions via non-parametric multiple imputation","volume":"27","author":"Ruan","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.juro.2010.05.085_bib30","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/0360-3016(94)90416-2","article-title":"Analysis of the probability and risk of cause-specific failure","volume":"29","author":"Caplan","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710037407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710037407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.05.085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:50:27Z","timestamp":1651197027000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.05.085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1016\/j.juro.2010.05.085"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.05.085","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}